Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$85.58
-4.1%
$90.00
$51.79
$101.40
$11.58B11.20 million shs1.50 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$56.11
+6.5%
$59.68
$47.31
$87.32
$2.60B0.53820,043 shs1.07 million shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$124.33
+5.6%
$121.80
$112.31
$212.00
$4.09B1.33630,444 shs462,972 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
-0.74%+1.72%+0.72%+2.08%+26.61%
Haemonetics Corporation stock logo
HAE
Haemonetics
-5.60%-10.97%-10.03%-19.20%-17.47%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-0.35%-2.53%+0.41%-19.80%-12.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$85.58
-4.1%
$90.00
$51.79
$101.40
$11.58B11.20 million shs1.50 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$56.11
+6.5%
$59.68
$47.31
$87.32
$2.60B0.53820,043 shs1.07 million shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$124.33
+5.6%
$121.80
$112.31
$212.00
$4.09B1.33630,444 shs462,972 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
-0.74%+1.72%+0.72%+2.08%+26.61%
Haemonetics Corporation stock logo
HAE
Haemonetics
-5.60%-10.97%-10.03%-19.20%-17.47%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-0.35%-2.53%+0.41%-19.80%-12.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.88
Moderate Buy$104.3620.78% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.73
Moderate Buy$82.7847.42% Upside
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2.93
Moderate Buy$193.3855.11% Upside

Current Analyst Ratings Breakdown

Latest GMED, HAE, and IRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Boost Price TargetBuy$155.00 ➝ $157.00
5/1/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Lower Price TargetBuy$198.00 ➝ $180.00
5/1/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Lower Price TargetOverweight$215.00 ➝ $175.00
5/1/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Lower Price TargetOverweight$200.00 ➝ $180.00
5/1/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Boost Price TargetBuy$254.00 ➝ $255.00
4/21/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Reiterated RatingSell (D-)
4/15/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
Reiterated RatingHold (C+)
4/15/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Lower Price TargetBuy$200.00 ➝ $170.00
4/13/2026
Haemonetics Corporation stock logo
HAE
Haemonetics
Lower Price TargetOutperform$80.00 ➝ $70.00
4/9/2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Lower Price TargetNeutral$184.00 ➝ $147.00
3/18/2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
UpgradeStrong-Buy
(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.94B3.98$6.03 per share14.33$33.86 per share2.55
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.32B1.98$7.27 per share7.72$16.34 per share3.44
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$747.14M5.48N/AN/A$4.91 per share25.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$3.9421.9617.712.1018.30%12.57%10.87%5/7/2026 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.6315.4510.631.0913.31%27.32%9.61%5/7/2026 (Estimated)
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$44.55M-$0.86N/A95.17N/A-3.53%-10.26%-1.39%N/A

Latest GMED, HAE, and IRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.92N/AN/AN/A$740.35 millionN/A
5/7/2026Q4 2026
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.28$1.29+$0.01-$0.44$336.83 millionN/A
4/30/2026Q1 2026
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.56-$0.35+$0.21-$0.43$194.11 million$199.39 million
2/24/2026Q4 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.06$1.28+$0.22$1.03$803.29 million$826.42 million
2/19/2026Q4 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$0.02$0.29+$0.27$0.17$202.61 million$208.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.26
2.74
Haemonetics Corporation stock logo
HAE
Haemonetics
1.01
1.75
1.15
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
4.03
5.17
4.98

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
0.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000135.25 million110.39 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02346.47 million45.62 millionOptionable
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2,40032.86 million32.54 millionOptionable

Recent News About These Companies

iRhythm (IRTC) Q1 2026 Earnings Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Globus Medical stock logo

Globus Medical NYSE:GMED

$85.58 -3.65 (-4.09%)
As of 03:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics stock logo

Haemonetics NYSE:HAE

$56.11 +3.44 (+6.53%)
As of 03:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

iRhythm Technologies stock logo

iRhythm Technologies NASDAQ:IRTC

$124.32 +6.63 (+5.63%)
As of 03:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.